Compare FSSL & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSSL | INMD |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.5M | 857.4M |
| IPO Year | 2025 | 2018 |
| Metric | FSSL | INMD |
|---|---|---|
| Price | $11.80 | $14.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $16.17 |
| AVG Volume (30 Days) | 224.0K | ★ 396.6K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.30 |
| P/E Ratio | ★ $9.70 | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.75 | $12.72 |
| 52 Week High | $14.49 | $16.74 |
| Indicator | FSSL | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 29.97 |
| Support Level | $11.43 | $13.27 |
| Resistance Level | $11.90 | $14.18 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 47.47 | 4.44 |
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing mainly in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest mainly in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.